- Home
- THC vs INCY Comparison
THC vs INCY Comparison
Compare THC & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THC | INCY |
|---|---|---|
| Founded | 1967 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 17.0B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | THC | INCY |
|---|---|---|
| Price | $214.82 | $101.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 20 |
| Target Price | ★ $222.00 | $90.71 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 10-28-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3878.02 |
| EPS | ★ 14.57 | 5.90 |
| Revenue | ★ $20,846,000,000.00 | $4,813,105,000.00 |
| Revenue This Year | $3.98 | $19.33 |
| Revenue Next Year | $4.39 | $10.47 |
| P/E Ratio | ★ $14.82 | $17.17 |
| Revenue Growth | N/A | ★ 18.09 |
| 52 Week Low | $109.82 | $53.56 |
| 52 Week High | $221.00 | $109.28 |
Technical Indicators
Market Signals| Indicator | THC | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 52.40 |
| Support Level | $212.86 | $100.30 |
| Resistance Level | $221.00 | $107.61 |
| Average True Range (ATR) | 6.02 | 2.83 |
| MACD | 2.22 | -0.89 |
| Stochastic Oscillator | 82.11 | 14.60 |
Price Performance
Historical ComparisonAbout THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.